Sergey Ivanov Email and Phone Number

Molecular biology and medical genetics professional with long-standing experience in human genetics and diagnostics. Versed in collaborative R&D research (target discovery, drug efficacy models, etc.) in the fast-paced environment of NCI-designated cancer centers. Collaborated with Rosetta Genomics, AstraZeneca, Plexxikon, and Ignyta. • Using molecular profiling performed annotation/curation of clinical variants, identified and validated novel clinical markers and therapeutic targets for kidney, lung, breast, head and neck cancers, mesothelioma as well as inherited kidney diseases;• Turned research concepts into new clinical tools and strategies by providing novel molecular targets and performing drug efficacy studies in vitro and on patient-derived mouse xenografts;• Reported on the role of TrkC, a neurotrophic receptor tyrosine kinase, in a radiation-resistant neuroinvasive cancer, adenoid cystic carcinoma, and performed preclinical studies of Trk inhibitors developed by AstraZeneca, Plexxikon and Ignyta; • Described activation of NOTCH1 in adenoid cystic carcinoma and investigated DAPT as a mono-therapy and in combination with radiation;• Established roles of miR-31 and HAPLN1 as a tumor suppressor and oncoprotein, respectively, in mesothelioma;• Published more than 50 papers in high-impact journals such as Nature Genetics, PNAS, Cancer Research, Clinical Cancer Research, Oncogene, etc;• Was funded by NIH and private foundations, awarded for best publication and acknowledged in Vanderbilt and Yale press releases